

Abstracts to be presented at 40th Annual SABCS — December 5-9, 2017

WEDNESDAY December 6, 2017

Program Number: GS1-02

NSABP B-47 (NRG Oncology): Phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C) → weekly paclitaxel (WP), or docetaxel (T) and C with or without a year of trastuzumab (H) in women with node-positive or high-risk node-negative invasive breast cancer (IBC) expressing HER2 staining intensity of IHC 1+ or 2+ with negative FISH (HER2-Low IBC).

Fehrenbacher L, Cecchini RS, Geyer CE, Rastogi P, Costantino JP, Atkins JN, Polikoff J, Boileau J-F, Provencher L, Stokoe C, Moore TD, Robidoux A, Borges V, Albain KS, Swain SM, Paik S, Mamounas EP, Wolmark N.

Presenter: Louis Fehrenbacher

Session Title: General Session 1 — Hall 3

Session Date & Time: Wednesday 12-6-2017; 9:30 AM - 11:15 AM

Presentation Time: 9:45 AM - 10:00 AM

THURSDAY December 7, 2017

Program Number: P2-11-01

Effects of radiotherapy on breast cancer outcomes among stage I, low-recurrence risk, hormone-sensitive breast cancer: Pooled analysis of individual data from phase III trials.

Jayasekera JC, Schechter C, Jaggi R, White J, Chapman JA-W, Whelan T, Sparano JA, Anderson SJ, Fyles A, Sauerbrei W, Zellars RC, Li Y, Song J, Julian T, Berry D, Feuer EJ, Luta G, Mandelblatt JS.

Presenter: Jayasekera, JC

Session Title: Treatment: Radiotherapy

Location: Poster Session 2 — Hall 1

Session Date & Time: Thursday, 12-7-2017; 7:00 AM-9:00 AM

Program Number: PD3-18

The NSABP/NRG 8-gene signature accurately predicts degree of benefit from trastuzumab in Alliance/NCCTG N9831: Validation of the 8-gene signature in an independent clinical trial.

Pogue-Geile KL, Song N, Serie DJ, Thompson AE.

Presenter: Kay Pogue-Geile

Session Title: Novel Drugs / Predicting Response for HER2+ Breast Cancer

Location: Spotlight Poster Discussion 3 — Stars at Night Ballroom 1 & 2

Session Date & Time: Thursday, 12-7-2017; 7:00 AM- 7:45 AM, Attend poster; 7:45 AM - 9 AM Poster discussion.



Abstracts to be Presented at 40th Annual SABCS — December 5-9, 2017

THURSDAY December 7, 2017 con't

Program Number: OT2-03-02

NRG Oncology/NSABP B-51/RTOG 1304: A phase III clinical trial to determine if chest wall and regional nodal radiotherapy post mastectomy or the addition of RNRT to breast RT post breast-conserving surgery reduces invasive cancer recurrence-free interval in patients with positive axillary nodes who are ypN0 after neoadjuvant chemotherapy.

Mamounas EP, Bandos H, White JR, Julian TB, Khan AJ, Shaitelman SF, Torres MA, Vicini FA, Ganz PA, McCloskey SA, Paik S, Gupta N, Li XA, DiCostanzo DJ, Costantino JP, Curran, Jr WJ, Wolmark N

Presenter: Eleftherios P Mamounas

Session Title: Ongoing Trials - Radiotherapy

Location: Ongoing Trials Poster Session 2 – Hall 1

Session Date & Time: Thursday, 12-7-2017; 5:00 PM- 7:00 PM

FRIDAY December 8, 2017

Program Number: OT3-05-05

MonarchE: A randomized, open-label, phase 3 study of abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone in patients with high risk, node positive, early stage, HR+, HER2- breast cancer.

Rastogi P, Toi M, Harbeck N, Bourayou N, Frenzel M, Johnston S.

Presenter: Priya Rastogi

Session Title: Ongoing Trials - Targeted- CDH 4/6

Location: Ongoing Trials Poster Session 3 – Hall 1

Session Date & Time: Friday, 12-8-2017; 5:00 PM- 7:00 PM